Sat, Jul 26, 2014, 9:35 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Prana Biotechnology Limited Message Board

kadaicher1 35 posts  |  Last Activity: Jul 5, 2014 11:58 PM Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • kadaicher1 kadaicher1 Jul 5, 2014 11:58 PM Flag

    I also think Prana are on the right track. They need to do more than slowing the atrophy. Prana have demonstrated they can affect the process and I agree now need to escalate the dose.
    There is a normal brain atrophy rate in the elderly and I would like to see them go after that as well. That may be where AD can be eliminated.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 3, 2014 4:28 PM Flag

    Here, but unable to attend.Everything changes so fast. When the first stage of IMAGINE ended, and all they saw to that stage was a reduction in brain atrophy, we didn't know brain atrophy was the most reliable marker of degeneration. Now we know. Many were saying the drug is right and the dose too low. Now we have crossovers in the extension trial to confirm drug related reduction in atrophy rate. Question is will they go after AD again with a higher dose, or easier targets like early HD and PD with 434, or even a combination. I hope their talks will be available on line.

    Sentiment: Strong Buy

  • Reply to

    PRAN HAS HIGHEST CASH POSITION EVER OF 41 MILLION

    by rkf302 Jun 30, 2014 2:20 PM
    kadaicher1 kadaicher1 Jul 3, 2014 1:13 AM Flag

    Prana can do a lot with 10 million. 41 million has to be very comfortable for them. When the Phase3 HD is announced there should be a spike. The new Parkinsons drug should cause some interest. The remaining AD results will be very interesting and will shed more light on future direction there. I would like to see a major effort into Parkinson's and HD before the final AD results.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 22, 2014 2:35 PM Flag

    I think it was worth a shot. From the previous trials they saw a natural decrease in AB42, now a reduction in brain atrophy in two trials. It did reduce plaque. They built more safety profile, and an Alzheimer's trial is still running. That PBT2 did not reduce AB42 in plasma after clearly demonstrating PBT2 reduces AD42 in the brain(CSF) is also important info.

    Sentiment: Strong Buy

  • Reply to

    So, who is lurking?

    by inversor86 Jun 18, 2014 4:17 PM
    kadaicher1 kadaicher1 Jun 22, 2014 2:24 PM Flag

    Still here with half of my stock and still in 6 digits. The tiny IMAGINE trial managed to somehow hurt confidence in the Reach2HD results. The co has stated they will spend some time on the results, but I cannot see how anything has changed regarding time to market for HD.
    Still a reduction in brain atrophy to look at in the IMAGINE extension placebo crossovers and maybe some longer term effects.
    I also happen to think there will soon be a major effort into Parkinson's.
    Don't have much time to post these days. I will finish a project I am on shortly and that will change. Good luck to fellow longs.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 12, 2014 12:42 AM Flag

    HD has always been the route to market and not much has changed there. Stay tuned for a short trial for approval in HD. NOTHING regarding that route to market has changed since the 500m market cap. Copper you have very selective vision. HD looks strong in early stage HD and the PD drug about to enter the clinic has spectacular pre clinical results. The AD trial is still ongoing.

    Sentiment: Strong Buy

  • Things are looking good for further development. Anyone who says different has not done their homework.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 11, 2014 12:14 PM Flag

    Thick as two short planks. A company with a blockbuster drug has a market cap closer to 10 billion. This company does have very high potential for a blockbuster.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 8, 2014 12:59 AM Flag

    Not much doubt their atrophy will slow. That was seen in a very small HD sample, then the AD trial, and probably now in the extension trial. I think that will be fairly big news, because it will prove disease modification in that biomarker. We already know if decreases the toxic AB42 in the brain only. The IMAGINE trial did not pick up a corresponding AB42 decrease in the blood. With a stellar safety profile, I think they are ready to raise the dose.

    Sentiment: Strong Buy

  • which has already demonstrated a slowing of brain atrophy. That is what you may expect given the research results showing restoration of neurons, synapses etc. Alzheimer's is a very complicated condition and PBT2, at this or higher doses may be a big part of the answer. Let's see what happens with 24 months treatment. The AD effort is a long way from over.
    That the small IMAGINE trial did not show any cognition changes over a year in very early patients where there is almost no deterioration is not so surprising. 24 months may show a different result.
    Meanwhile just waiting on word of the HD phase3 pivotal for approval.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jun 1, 2014 2:22 AM Flag

    I think it tells us Prana is going to have to go for a higher dose. I know it is a mouse study and a human study, but everything so far indicates a higher dose. It is probably safer to take care of the HD trial before they do that. With the 10 fold dose, the reduction in atrophy turned into a size increase. Lindquist identified where it gets tricky. In her model she demonstrated that MPACs were most efficious just before reaching toxicity. I think Prana have a little more work to do on AD while they are doing the HD phase3.
    Thanks for posting that Pivalde.

    Sentiment: Strong Buy

  • Reply to

    When will the dilution hit?

    by cramerblows_a_s_s May 29, 2014 11:19 AM
    kadaicher1 kadaicher1 May 30, 2014 2:39 AM Flag

    That is an old article which was true when it was written. It is no longer accurate. They have enough to progress the HD trial for approval, they have one of the worlds top HD investigators now on the board. After another 12 months there could be some raising. It depends how hard they want to proceed with the Parkinson's drug. Anyway, at that point the price will be higher with the HD trial on and maybe the IMAGINE extension trial will kick out some more useful data.
    Now would probably be the time to plan to increase dosage with IMAGINE AD patients who wish to continue.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 May 28, 2014 1:00 PM Flag

    Or, this was way oversold, so it will go back up, which it is doing.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 May 21, 2014 1:14 PM Flag

    Prana does not need saving. THey have some nice HD results so far and enough cash for the trial. Now they have one of the worlds top authorities on HD come on board. Dr Shoulson founded the volunteer Huntington's Study Group and was the principal investigator in the trial for the only approved HD drug. I know you know all this, which perhaps makes you a lying POS.

    Sentiment: Strong Buy

  • Reply to

    Info on Professor Ira Shoulson new director

    by futurequestnow May 15, 2014 10:14 PM
    kadaicher1 kadaicher1 May 20, 2014 10:31 AM Flag

    Yes, a lot of traders have been speaking rubbish about the HD resuts, but Dr Shoulson has the background to speak with authority. To have him speaking to the FDA will mean a lot.

    Sentiment: Strong Buy

  • Reply to

    Info on Professor Ira Shoulson new director

    by futurequestnow May 15, 2014 10:14 PM
    kadaicher1 kadaicher1 May 20, 2014 12:29 AM Flag

    To see a guy like Dr Shoulson joining the board to drive development in HD and PD, where he is a world leader, is encouraging. He has clearly seen the trial results so far as holding promise. He has been principal investigator in about 25 trials over his career. He ran the trial for the only FDA approved HD drug so far.

    Sentiment: Strong Buy

  • Reply to

    Significant Development for PRANA

    by rohas222 May 19, 2014 10:21 AM
    kadaicher1 kadaicher1 May 19, 2014 11:54 PM Flag

    That could prove interesting for HD in particular. Any EF changes in at risk patients could be a time to head off onset. The trial indicated a stat sig effect in the earliest stage patients, but I suspect PBT2 would be even more effective just pre onset.
    This change also raises the possibility of using the movement disorder drug PBT434 against HD earlier than previously thought possible. Although 434 has been designed for Parkinson's, iron build has been linked to predicting onset of HD and that is where 434 could help It was referred to as a movement disorder drug by Prana, rather than just a
    Parkinson's drug.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 May 6, 2014 8:07 AM Flag

    Investors need to remember PBT2 beat market expectations on the HD results, and now Prana are preparing for a pivotal phase 3 for approval. Last drug approved for HD was done in just a 3 month trial. Sure if they go for early stage disease the trial may take longer than that, but Prana are shooting for 2016 or 17 NDA.

    Sentiment: Strong Buy

  • Prana had no money back then, no HD efficacy in humans, and an HD phase1a trial just looking for safety as a primary endpoint.
    Now they have an HD result that beat market expectations in HD. Reach2HD discovered not only trends across all measures, but was stat sig in a very important measure and identified an ideal phase3 target where it was stat sig over a group of tests in the pre specified early stage group.
    They are now cashed up with 40m and planning a phase 3 on those results.
    Shorts may be able to convince holders to sell, but it is a con. This is very cheap right now.
    The IMAGINE extension trial still has about 8 months to run.
    Add to that a PD drug with strong preclinical results reaching the clinic this year.

    Sentiment: Strong Buy

  • Reply to

    I removed my prior post

    by aknb9 Apr 3, 2014 10:17 AM
    kadaicher1 kadaicher1 May 5, 2014 6:45 AM Flag

    The cause of the abnormal placebo was the placebo size. I don't think there can be any credible argument there. You know that. That brain atrophy was not accompanied by any cognition result was explained very well. Why do you think they went for a biomarker for a primary end point. Not only was it explained, but their trial design indicated they always thought that would be a possibility. It just depends how you look at it. Prana knew biomarker changes could happen before cognition changes.

    Sentiment: Strong Buy

PRAN
2.2999-0.0501(-2.13%)Jul 25 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.